---
title: "Curis | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 3.176 M"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/264724211.md"
datetime: "2025-11-06T21:35:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264724211.md)
  - [en](https://longbridge.com/en/news/264724211.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264724211.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/264724211.md) | [繁體中文](https://longbridge.com/zh-HK/news/264724211.md)


# Curis | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 3.176 M

Revenue: As of FY2025 Q3, the actual value is USD 3.176 M, beating the estimate of USD 2.86 M.

EPS: As of FY2025 Q3, the actual value is USD -0.49.

EBIT: As of FY2025 Q3, the actual value is USD -7.004 M.

### Segment Revenue

-   **Revenues, net**: $3.2 million for the three months ended September 30, 2025, compared to $2.9 million for the same period in 2024, representing an 8% increase. For the nine months ended September 30, 2025, revenues were $8.3 million, compared to $7.6 million in 2024, a 10% increase.

### Operational Metrics

-   **Net Loss**: $7.7 million for the three months ended September 30, 2025, compared to $10.1 million for the same period in 2024, a 23% decrease. For the nine months ended September 30, 2025, net loss was $26.9 million, compared to $33.8 million in 2024, a 20% decrease.
-   **Research and Development Expenses**: $6.4 million for the three months ended September 30, 2025, compared to $9.7 million in 2024, a 34% decrease. For the nine months ended September 30, 2025, these expenses were $22.4 million, compared to $29.6 million in 2024, a 24% decrease.
-   **General and Administrative Expenses**: $3.7 million for the three months ended September 30, 2025, compared to $3.8 million in 2024, a 3% decrease. For the nine months ended September 30, 2025, these expenses were $11.2 million, compared to $13.4 million in 2024, a 17% decrease.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $20.8 million for the nine months ended September 30, 2025, compared to - $30.3 million in 2024.
-   **Net Cash Provided by Financing Activities**: $9.9 million for the nine months ended September 30, 2025, compared to - $5.4 million used in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: Curis, Inc. plans to continue focusing on the development of emavusertib, an IRAK4 inhibitor, with ongoing clinical trials in various cancer indications. The company anticipates additional data from the TakeAim Lymphoma Phase 1⁄2 study in the fourth quarter of 2025 and plans to initiate a new clinical study in CLL later this year or early next year, with data expected in the fourth quarter of 2026.
-   **Non-Core Business**: The company sold its interest in Curis Royalty LLC, including the Erivedge intellectual property, to TPC Investments Royalty LLC, which will result in a gain and extinguishment of the liability related to the sale of future royalties in the fourth quarter of 2025.

### 相关股票

- [Curis (CRIS.US)](https://longbridge.com/zh-CN/quote/CRIS.US.md)

## 相关资讯与研究

- [AngioDynamics Q3 revenue beats estimates on Med Tech strength, raises outlook](https://longbridge.com/zh-CN/news/281504186.md)
- [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/zh-CN/news/281530653.md)
- [Cintas (CTAS) Valuation Check After Q3 Results And Higher Fiscal 2026 Guidance](https://longbridge.com/zh-CN/news/281225115.md)
- [Nike Takes 'Intentional' Hit To Clear 'Unhealthy Inventory' In Q3 As CEO Eyes Turnaround By Year-End](https://longbridge.com/zh-CN/news/281362844.md)
- [Nike Delivers Q3 Earnings Beat As Turnaround Progresses, Shares Slide](https://longbridge.com/zh-CN/news/281243092.md)